{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:03:54Z","timestamp":1772640234836,"version":"3.50.1"},"reference-count":128,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013098","name":"Scientific and Innovative Action Plan of Shanghai","doi-asserted-by":"publisher","award":["20JC1411000"],"award-info":[{"award-number":["20JC1411000"]}],"id":[{"id":"10.13039\/501100013098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013098","name":"Scientific and Innovative Action Plan of Shanghai","doi-asserted-by":"publisher","award":["20S11904700"],"award-info":[{"award-number":["20S11904700"]}],"id":[{"id":"10.13039\/501100013098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803529"],"award-info":[{"award-number":["81803529"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773620"],"award-info":[{"award-number":["81773620"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073752"],"award-info":[{"award-number":["82073752"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21YF1401900"],"award-info":[{"award-number":["21YF1401900"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the paradigm in hematological malignancies treatment, driving an ever-expanding number of basic research and clinical trials of genetically engineering T cells to treat solid tumors. CAR T-cell therapies based on the antibodies targeting Mesothelin, CEA, EGFR, EGFR, MUC1, DLL3, and emerging novel targets provide promising efficacy for lung cancer patients. However, clinical application of CAR T-cell therapy against lung cancer remains limited on account of physical and immune barriers, antigen escape and heterogeneity, on-target off-tumor toxicity, and many other reasons. Understanding the evolution of CAR structure and the generalizable requirements for manufacturing CAR T cells as well as the interplay between lung tumor immunology and CAR T cells will improve clinical translation of this therapeutic modality in lung cancer. In this review, we systematically summarize the latest advances in CAR T-cell therapy in lung cancer, focusing on the CAR structure, target antigens, challenges, and corresponding new strategies.<\/jats:p>","DOI":"10.1093\/abt\/tbac006","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T13:44:20Z","timestamp":1646228660000},"page":"73-83","source":"Crossref","is-referenced-by-count":6,"title":["Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer"],"prefix":"10.1093","volume":"5","author":[{"given":"Caili","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics , School of Pharmacy, Fudan University, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianwen","family":"Ju","sequence":"additional","affiliation":[{"name":"Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics , School of Pharmacy, Fudan University, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1654-5550","authenticated-orcid":false,"given":"Xuyao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics , School of Pharmacy, Fudan University, Shanghai 201203, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"2022102704575156900_ref1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2022102704575156900_ref2","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","article-title":"Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin","volume":"16","author":"Oser","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022102704575156900_ref3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"key":"2022102704575156900_ref4","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","article-title":"CAR T cells: continuation in a revolution of immunotherapy","volume":"21","author":"Singh","year":"2020","journal-title":"Lancet Oncol"},{"key":"2022102704575156900_ref5","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/j.1349-7006.2007.00586.x","article-title":"Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and\/or major histocompatibility complex class I chain related molecules A\/B","volume":"98","author":"Baba","year":"2007","journal-title":"Cancer Sci"},{"key":"2022102704575156900_ref6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2022102704575156900_ref7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"2022102704575156900_ref8","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A Phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2022102704575156900_ref9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol Rev"},{"key":"2022102704575156900_ref10","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Onco Targets Ther"},{"key":"2022102704575156900_ref11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","article-title":"CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity","volume":"8","author":"Kueberuwa","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"2022102704575156900_ref12","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1182\/blood.V128.22.816.816","article-title":"IL-18 secreting CAR T cells enhance cell persistence, induce prolonged B cell aplasia and eradicate CD19+ tumor cells without need for prior conditioning","volume":"128","author":"Avanzi","year":"2016","journal-title":"Blood"},{"key":"2022102704575156900_ref13","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"key":"2022102704575156900_ref14","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"key":"2022102704575156900_ref15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"2022102704575156900_ref16","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3390\/cancers12051302","article-title":"Adaptor CAR platforms-next generation of T cell-based cancer immunotherapy","volume":"12","author":"Arndt","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2022102704575156900_ref17","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"2022102704575156900_ref18","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \"off-the-shelf\" adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res"},{"key":"2022102704575156900_ref19","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2022102704575156900_ref20","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022102704575156900_ref21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T cells, and universal CAR T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2022102704575156900_ref22","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T cell therapy for cancer in the clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Immunol"},{"key":"2022102704575156900_ref23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/scbi.1998.0119","article-title":"The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues","volume":"9","author":"Hammarstr\u00f6m","year":"1999","journal-title":"Semin Cancer Biol"},{"key":"2022102704575156900_ref24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.lungcan.2011.11.012","article-title":"Carcinoembryonic antigen (CEA) as tumor marker in lung cancer","volume":"76","author":"Grunnet","year":"2012","journal-title":"Lung Cancer"},{"key":"2022102704575156900_ref25","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s13277-012-0344-0","article-title":"The relevance of serum carcinoembryonic antigen as an indicator of brain metastasis detection in advanced non-small cell lung cancer","volume":"33","author":"Lee","year":"2012","journal-title":"Tumour Biol"},{"key":"2022102704575156900_ref26","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol Ther"},{"key":"2022102704575156900_ref27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120082","article-title":"EGFR targeting for cancer therapy: pharmacology and immunoconjugates with drugs and nanoparticles","volume":"592","author":"Santos","year":"2021","journal-title":"Int J Pharm"},{"key":"2022102704575156900_ref28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol Oncol"},{"key":"2022102704575156900_ref29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","article-title":"EGFR mutations and lung cancer","volume":"6","author":"Cunha","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"2022102704575156900_ref30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/0008-5472.CAN-18-1281","article-title":"Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer","volume":"79","author":"Murtuza","year":"2019","journal-title":"Cancer Res"},{"key":"2022102704575156900_ref31","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/14712598.2018.1452906","article-title":"Cetuximab for treating non-small cell lung cancer","volume":"18","author":"Mazzarella","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"2022102704575156900_ref32","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/14712598.2018.1508445","article-title":"Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies","volume":"18","author":"Noia","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"2022102704575156900_ref33","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2022102704575156900_ref34","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov"},{"key":"2022102704575156900_ref35","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer","volume":"59","author":"Feng","year":"2016","journal-title":"Sci China Life Sci"},{"key":"2022102704575156900_ref36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11684-019-0683-y","article-title":"Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy","volume":"13","author":"Zhang","year":"2019","journal-title":"Front Med"},{"key":"2022102704575156900_ref37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov"},{"key":"2022102704575156900_ref38","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022102704575156900_ref39","doi-asserted-by":"crossref","first-page":"11694","DOI":"10.18632\/oncotarget.3429","article-title":"High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis","volume":"6","author":"Thomas","year":"2015","journal-title":"Oncotarget"},{"key":"2022102704575156900_ref40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JTO.0000000000000404","article-title":"Mucins in lung cancer: diagnostic, prognostic, and therapeutic implications","volume":"10","author":"Lakshmanan","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2022102704575156900_ref41","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1007\/s12032-010-9752-4","article-title":"Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer","volume":"28","author":"Situ","year":"2011","journal-title":"Med Oncol"},{"key":"2022102704575156900_ref42","first-page":"337","article-title":"MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion","volume":"35","author":"Gao","year":"2009","journal-title":"Int J Oncol"},{"key":"2022102704575156900_ref43","first-page":"4443","article-title":"MUC1 downregulation inhibits non-small cell lung cancer progression in human cell lines","volume":"14","author":"Xu","year":"2017","journal-title":"Exp Ther Med"},{"key":"2022102704575156900_ref44","article-title":"PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells","volume":"6","author":"Wei","year":"2017","journal-title":"Onco Targets Ther"},{"key":"2022102704575156900_ref45","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.lungcan.2017.11.018","article-title":"Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer","volume":"115","author":"Tanaka","year":"2018","journal-title":"Lung Cancer"},{"key":"2022102704575156900_ref46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: an emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2022102704575156900_ref47","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small-cell lung cancer: results from the phase II TRINITY study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022102704575156900_ref48","doi-asserted-by":"crossref","first-page":"S971","DOI":"10.1016\/j.jtho.2018.08.1826","article-title":"P3.12-03 targeting DLL3 with AMG 757, a BiTE\u00ae antibody construct, and AMG 119, a CAR-T, for the treatment of SCLC","volume":"13","author":"Giffin","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2022102704575156900_ref49","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fonc.2019.00248","article-title":"Next-generation cancer immunotherapy targeting Glypican-3","volume":"9","author":"Shimizu","year":"2019","journal-title":"Front Oncol"},{"key":"2022102704575156900_ref50","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181147","article-title":"Glypican-3 promotes cell proliferation and tumorigenesis through up-regulation of \u03b2-catenin expression in lung squamous cell carcinoma","volume":"39","author":"Wang","year":"2019","journal-title":"Biosci Rep"},{"key":"2022102704575156900_ref51","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.18632\/oncotarget.6595","article-title":"Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"2022102704575156900_ref52","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41389-020-00257-z","article-title":"Targeting PD-L1 in non-small cell lung cancer using CAR T cells","volume":"9","author":"Liu","year":"2020","journal-title":"Oncogene"},{"key":"2022102704575156900_ref53","first-page":"37","article-title":"Insights into CD47\/SIRP\u03b1 axis-targeting tumor immunotherapy","volume":"1","author":"Zhang","year":"2018","journal-title":"Antib Ther"},{"key":"2022102704575156900_ref54","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5575260","article-title":"Third-generation anti-CD47-specific CAR-T cells effectively kill cancer cells and reduce the genes expression in lung cancer cell metastasis","volume":"2021","author":"La","year":"2021","journal-title":"J Immunol Res"},{"key":"2022102704575156900_ref55","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13045-020-00944-9","article-title":"Targeting EphA2 in cancer","volume":"13","author":"Xiao","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2022102704575156900_ref56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tranon.2017.10.009","article-title":"Chimeric antigen receptor-modified T cells redirected to EphA2 for the immunotherapy of non-small cell lung cancer","volume":"11","author":"Li","year":"2018","journal-title":"Transl Oncol"},{"key":"2022102704575156900_ref57","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/0008-5472.CAN-15-0717","article-title":"EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer","volume":"76","author":"Amato","year":"2016","journal-title":"Cancer Res"},{"key":"2022102704575156900_ref58","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1158\/0008-5472.CAN-14-1831","article-title":"Targeting LUNX inhibits non-small cell lung cancer growth and metastasis","volume":"75","author":"Zheng","year":"2015","journal-title":"Cancer Res"},{"key":"2022102704575156900_ref59","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.omto.2020.04.008","article-title":"LunX-CAR T cells as a targeted therapy for non-small cell lung cancer","volume":"17","author":"Hu","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"2022102704575156900_ref60","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13045-019-0793-7","article-title":"MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells","volume":"12","author":"Mao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2022102704575156900_ref61","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1038\/s41388-018-0187-2","article-title":"Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models","volume":"37","author":"Crossland","year":"2018","journal-title":"Oncogene"},{"key":"2022102704575156900_ref62","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fimmu.2020.00099","article-title":"CAR T cells redirected to CD44v6 control tumor growth in lung and ovary adenocarcinoma bearing mice","volume":"11","author":"Porcellini","year":"2020","journal-title":"Front Immunol"},{"key":"2022102704575156900_ref63","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","article-title":"Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells","volume":"75","author":"Lo","year":"2015","journal-title":"Cancer Res"},{"key":"2022102704575156900_ref64","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11427-019-9665-8","article-title":"Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment","volume":"63","author":"Zhao","year":"2020","journal-title":"Sci China Life Sci"},{"key":"2022102704575156900_ref65","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"2022102704575156900_ref66","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2022102704575156900_ref67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2022102704575156900_ref68","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"2022102704575156900_ref69","doi-asserted-by":"crossref","first-page":"eaax7969","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci Immunol"},{"key":"2022102704575156900_ref70","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"2022102704575156900_ref71","first-page":"56","article-title":"Cytokine release syndrome. J Immunother","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"Cancer"},{"key":"2022102704575156900_ref72","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"2022102704575156900_ref73","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"key":"2022102704575156900_ref74","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"key":"2022102704575156900_ref75","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(03)15326-3","article-title":"Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock","volume":"363","author":"Pathan","year":"2004","journal-title":"Lancet"},{"key":"2022102704575156900_ref76","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"key":"2022102704575156900_ref77","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"2022102704575156900_ref78","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"2022102704575156900_ref79","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2022102704575156900_ref80","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1074-7613(04)00021-4","article-title":"The collagen binding alpha1beta1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection","volume":"20","author":"Ray","year":"2004","journal-title":"Immunity"},{"key":"2022102704575156900_ref81","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1172\/JCI24482","article-title":"Preferential migration of effector CD8+ T cells into the interstitium of the normal lung","volume":"115","author":"Galkina","year":"2005","journal-title":"J Clin Invest"},{"key":"2022102704575156900_ref82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.immuni.2008.05.011","article-title":"The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections","volume":"29","author":"Kohlmeier","year":"2008","journal-title":"Immunity"},{"key":"2022102704575156900_ref83","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.immuni.2013.09.013","article-title":"Lung airway-surveilling CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A virus","volume":"39","author":"Sl\u00fctter","year":"2013","journal-title":"Immunity"},{"key":"2022102704575156900_ref84","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.cell.2020.11.019","article-title":"The identity of human tissue-emigrant CD8(+) T cells","volume":"183","author":"Buggert","year":"2020","journal-title":"Cell"},{"key":"2022102704575156900_ref85","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.jaci.2017.12.998","article-title":"CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor T-cell responses","volume":"142","author":"Cheng","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2022102704575156900_ref86","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/JTO.0b013e3181f8a1bd","article-title":"The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer","volume":"6","author":"Bremnes","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2022102704575156900_ref87","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1172\/JCI45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J Clin Invest"},{"key":"2022102704575156900_ref88","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021012811","article-title":"Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma","author":"Sakemura","year":"2022","journal-title":"Blood"},{"key":"2022102704575156900_ref89","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","article-title":"T cell senescence and CAR-T cell exhaustion in hematological malignancies","volume":"11","author":"Kasakovski","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2022102704575156900_ref90","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-3-319-24932-2_5","article-title":"The microenvironment of lung cancer and therapeutic implications","volume":"890","author":"Mittal","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"2022102704575156900_ref91","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"2022102704575156900_ref92","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGF\u03b2 biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2022102704575156900_ref93","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi5781","article-title":"Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors","volume":"7","author":"Cadilha","year":"2021","journal-title":"Sci Adv"},{"key":"2022102704575156900_ref94","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"key":"2022102704575156900_ref95","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000676","article-title":"Inhibition of TGF-\u03b2-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer","volume":"8","author":"St\u00fcber","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2022102704575156900_ref96","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"key":"2022102704575156900_ref97","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1038\/s41467-018-07767-w","article-title":"Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer","volume":"9","author":"Jia","year":"2018","journal-title":"Nat Commun"},{"key":"2022102704575156900_ref98","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"2022102704575156900_ref99","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"2022102704575156900_ref100","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible Caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol Ther"},{"key":"2022102704575156900_ref101","doi-asserted-by":"crossref","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"2022102704575156900_ref102","doi-asserted-by":"crossref","first-page":"12178","DOI":"10.1002\/anie.202005432","article-title":"Chemically programmable and switchable CAR-T therapy","volume":"59","author":"Qi","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"key":"2022102704575156900_ref103","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41587-020-0580-6","article-title":"Metabolic engineering generates a transgene-free safety switch for cell therapy","volume":"38","author":"Wiebking","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2022102704575156900_ref104","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fonc.2019.00151","article-title":"Preclinical evaluation of bispecific adaptor molecule controlled folate receptor CAR-T cell therapy with special focus on pediatric malignancies","volume":"9","author":"Lu","year":"2019","journal-title":"Front Oncol"},{"key":"2022102704575156900_ref105","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022102704575156900_ref106","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm.4015","article-title":"Prospects for gene-engineered T cell immunotherapy for solid cancers","volume":"22","author":"Klebanoff","year":"2016","journal-title":"Nat Med"},{"key":"2022102704575156900_ref107","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022102704575156900_ref108","article-title":"C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer","volume":"5","author":"Rapp","year":"2016","journal-title":"Onco Targets Ther"},{"key":"2022102704575156900_ref109","article-title":"Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model","volume":"7","author":"Idorn","year":"2018","journal-title":"Onco Targets Ther"},{"key":"2022102704575156900_ref110","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.omto.2021.07.003","article-title":"CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells","volume":"22","author":"Li","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"2022102704575156900_ref111","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3892\/ijo.2014.2688","article-title":"Expression and clinical significance of CXCR5\/CXCL13 in human non-small cell lung carcinoma","volume":"45","author":"Singh","year":"2014","journal-title":"Int J Oncol"},{"key":"2022102704575156900_ref112","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz6667","article-title":"Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy","volume":"12","author":"Hao","year":"2020","journal-title":"Sci Transl Med"},{"key":"2022102704575156900_ref113","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200844","article-title":"STING agonist promotes CAR T cell trafficking and persistence in breast cancer","volume":"218","author":"Xu","year":"2021","journal-title":"J Exp Med"},{"key":"2022102704575156900_ref114","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s43018-020-00147-8","article-title":"Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma","volume":"2","author":"Ma","year":"2021","journal-title":"Nat Cancer"},{"key":"2022102704575156900_ref115","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"2022102704575156900_ref116","doi-asserted-by":"crossref","first-page":"5902","DOI":"10.1038\/s41467-020-19672-2","article-title":"Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9","volume":"11","author":"Liu","year":"2020","journal-title":"Nat Commun"},{"key":"2022102704575156900_ref117","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","article-title":"Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and Interleukin-15","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022102704575156900_ref118","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T cells releasing IL-18 convert to T-Bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid Tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep"},{"key":"2022102704575156900_ref119","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep"},{"key":"2022102704575156900_ref120","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"2022102704575156900_ref121","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"key":"2022102704575156900_ref122","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2022102704575156900_ref123","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/mt.2014.47","article-title":"Reversal of tumor immune inhibition using a chimeric cytokine receptor","volume":"22","author":"Leen","year":"2014","journal-title":"Mol Ther"},{"key":"2022102704575156900_ref124","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"2022102704575156900_ref125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci Transl Med"},{"key":"2022102704575156900_ref126","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3389\/fimmu.2020.01109","article-title":"CAR-T cells hit the tumor microenvironment: strategies to overcome tumor escape","volume":"11","author":"Rodriguez-Garcia","year":"2020","journal-title":"Front Immunol"},{"key":"2022102704575156900_ref127","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1158\/0008-5472.CAN-20-3941","article-title":"TGF\u03b2 Signaling activated by cancer-associated fibroblasts determines the histological signature of lung adenocarcinoma","volume":"81","author":"Sato","year":"2021","journal-title":"Cancer Res"},{"key":"2022102704575156900_ref128","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.ccell.2021.09.003","article-title":"Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms","volume":"39","author":"Hu","year":"2021","journal-title":"Cancer Cell"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbac006\/42807626\/tbac006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/5\/1\/73\/46650246\/tbac006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/5\/1\/73\/46650246\/tbac006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T05:00:06Z","timestamp":1666846806000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/5\/1\/73\/6534723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbac006","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1]]},"published":{"date-parts":[[2022,1,1]]}}}